Norvēģija - norvēģu - Statens legemiddelverk

fresenius kabi norge as - irinotekanhydrokloridtrihydrat - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml

Norvēģija - norvēģu - Statens legemiddelverk

accord healthcare b.v. - topotekanhydroklorid - konsentrat til infusjonsvæske, oppløsning - 1 mg/ ml

Norvēģija - norvēģu - Statens legemiddelverk

ebewe pharma ges.m.b.h nfg. kg - topotekanhydroklorid - konsentrat til infusjonsvæske, oppløsning - 1 mg/ ml

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib disodium - trombocytopeni - andre systemiske hemostatics - tavlesse er indisert for behandling av kronisk immun trombocytopeni (itp) hos voksne pasienter som er refraktære til andre behandlinger.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiske midler - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressive - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Norvēģija - norvēģu - Statens legemiddelverk

sanofi-aventis norge (3) - mesalazin - stikkpille - 500 mg

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - immunsuppressive - plakk psoriasistaltz er angitt for behandling av moderat til alvorlig plakkpsoriasis hos voksne som er kandidater for systemisk terapi. psoriasis arthritistaltz, alene eller i kombinasjon med metotreksat, er indisert for behandling av aktiv psoriasisartritt hos voksne pasienter som har respondert utilstrekkelig til, eller som er intolerante til en eller flere sykdomsmodifiserende antirevmatiske legemiddel (dmard) terapi.